Zimmer Biomet ZBH Stock Price Today

The company issued revenue guidance of $7.39 billion-$7.43 billion, compared to the consensus revenue estimate of $7.40 billion. The faster a company is growing, the more likely it is to be creating value for shareholders, especially if the growth is profitable. The 3-year average annual revenue growth rate of Zimmer Biomet Holdings is -5.1%, ranking worse than 78.54% of companies in the Medical Devices & Instruments industry. The 3-year average EBITDA growth rate is -11.8%, ranking worse than 78.49% of companies in the same industry. Investing in profitable companies, especially those that have demonstrated consistent profitability over the long term, poses less risk. Zimmer Biomet Holdings has been profitable 8 over the past 10 years.

The Wall Street rally in the first seven months of this year suffered a severe setback consecutively in August and September. Volatility continues in October as the Fed warned of one more rate hike of 25 basis points by the end of this year and a higher interest rate regime for a longer period. The first rate cut is not expected before September 2024 and the inflation rate is unlikely to decline to the central bank’s target rate of 2% before 2026. You can find your newly purchased ZBH stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, treasuries, and alternative assets. Although the market has recovered a bit of its momentum recently, stocks have still paused their run higher for long enough to present investors with an opportunity to buy while the buying is good.

TWLO is benefiting from accelerated digital transformation amid a growing hybrid working trend. TWLO’s selective acquisitions and strategic investments in businesses and technologies are enhancing its product portfolio and fortifying its what currency pairs should i select global presence. With that kind of print, CTVA might not seem an ideal candidate for high-growth S&P 500 stocks to buy. However, as boring as the underlying agricultural sector is, geopolitics has made (regrettably) more exciting.

Price Target and Rating

Zimmer Biomet is also pursuing strategic acquisitions to expand its presence in emerging markets and strengthen its position in existing markets. The company’s leadership team is led by President and CEO Bryan Hanson, who has been in his current role since 2017. Hanson has over 30 years of experience in the medical device industry and has held various executive positions in leading medical device companies. Additionally, Zimmer Biomet’s executive team includes Chief Financial Officer Suketu Upadhyay and Chief Operating Officer Ivan Tornos. The results are below, along with each company’s ticker, latest closing price, price to fair value ratio, fair value uncertainty, and its economic moat rating. Sekara was among those who had to try and keep up with the surprising moves among growth stocks this year.

• Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information.
• This market is expanding at a rapid pace on favorable demographics and growing utilization of musculoskeletal healthcare, particularly in emerging markets and under-penetrated developed markets.
• An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s.
• Zimmer Biomet is expanding its product portfolio through innovation and acquisitions.

Zimmer Biomet Holdings has an expected revenue and earnings growth rate of 6.7% and 9%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 0.8% over the last 60 days. The stock price of ZBH is currently trading the most important thing at a 31.2% discount to its 52-week high. Align Technology has an expected revenue and earnings growth rate of 6.6% and 13.1%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 0.1% over the last 30 days.

Zacks Research is Reported On:

As The Wall Street Journal reported, the current high interest-rate environment imposes significant headwinds against wind and solar developers. It’s so bad that the pessimism easily clouds a wave of government subsidies for green projects. Still, for the contrarian investor, NEE could be one of the enticing high-growth S&P 500 stocks. Also, its three-year revenue growth rate of 9.7% beats out 79.51% of its peers. In closing, analysts rate YUM a moderate buy with a $146 target, implying over 21% growth. When you add that SHW only gained less than 6% since the January opener, the notion seems even more absurd.

ROIC measures how well a company generates cash flow relative to the capital it has invested in its business. WACC is the rate that a company is expected to pay on average to all its security holders to finance its assets. If the ROIC is higher than the WACC, it implies the company is creating value for shareholders. For the past 12 months, Zimmer Biomet Holdings’s ROIC is 5.05, and its WACC is 7.61. Investing in companies with low financial strength could result in permanent capital loss.

For example, the increasing popularity of non-surgical treatments for orthopedic conditions could affect the demand for joint replacement products. Jared Holz, Mizuho health care sector strategist, joins the ‘Fast Money’ traders to discuss Novo Nordisj’s kidney trial outcomes and the impact of weight loss drugs on the health care sector. Banking services and bank accounts are offered by Jiko Bank, a division of Mid-Central National Bank, Member FDIC. The value each ZBH share was expected to gain vs. the value that each ZBH share actually gained. “We think that the Federal Reserve not only are they going to not be raising rates, we think their next move is actually going to be to start cutting rates next year.” Watching the market fall and the value of your investments sink along with it is never a good feeling — but it can bring along a better buying opportunity.

ZBH Price/Volume Stats

66.0% of employees surveyed would recommend working at Zimmer Biomet to a friend. Zimmer Biomet declared a quarterly dividend on Friday, August 25th. Shareholders of record on Friday, September 29th will be given a dividend of $0.24 per share on Tuesday, October 31st. This represents a $0.96 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date of this dividend is Thursday, September 28th.

Medical device maker Zimmer Biomet lifts profit forecast as surgeries rebound

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

High-Growth S&P 500 Stocks to Buy Now

Securities products offered by Open to the Public Investing are not FDIC insured. Apex Clearing Corporation, our clearing firm, has additional insurance coverage in excess of the regular SIPC limits. “So, again, with as much as growth has moved back down, we do think that now is a good time to move back to that market weight,” he wrote.

Our experts picked 7 Zacks Rank #1 Strong Buy stocks with the best chance to skyrocket within the next days. ALGN has launched its first subscription-based clear aligner program DSP worldwide. Within the Scanner business, ALGN is scaling up the production and distribution of iTero in several countries. Innovations and market expansion efforts are helping ALGN offset the impact of inflation and supply disruptions. The chart below shows the price performance of our five picks in the past month. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.

That said, Sekara warned that the magnificent seven trade has probably petered out by now, and gains for a group of stocks that have run so high so quickly this year will be harder to come by. Also, the skincare category has been gaining from consumers’ rising interest in self-care. ULTA’s solid performance was backed by the strong execution of its strategies and solid guest demand, with the latter gaining from exciting brand launches. While an important component of healthcare, arguably most folks wouldn’t consider ZBH as one of the high-growth S&P 500 stocks.

Zimmer Biomet’s spinoff ZimVie to have about $1 billion in revenue in 2022

The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which etoro forex broker review no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Alternative Assets.Brokerage services for alternative assets available on Public are offered by Dalmore Group, LLC (“Dalmore”), member of FINRA & SIPC.

He pointed out that the sectors closely correlated to interest rates look particularly undervalued right now, including utilities and real estate. Still, the restaurant operator – which owns several popular fast-food brands – may benefit from the trade-down effect. Basically, consumers will trade down from pricey eateries to more affordable fare, which theoretically should benefit Yum. In a Reuters report in August, Yum beat estimates for quarterly comparable sales and profit due to stronger demand for cheaper meals at KFC.

Based on an average trading volume of 1,590,000 shares, the days-to-cover ratio is currently 1.7 days. Zimmer Biomet is expanding its product portfolio through innovation and acquisitions. The company has a robust pipeline of new products in development, including the Persona Revision Knee System and the ROSA Knee System.

Investment in these stocks with a favorable Zacks Rank should be prudent going forward. Over the past few years, Zimmer Biomet has reported steady financial performance. The company has reported increased revenue and profit margin for the past several years while also reporting a debt-to-equity ratio indicating a relatively low debt level. In 2021, the company also announced a share repurchase program of up to $1 billion, demonstrating its commitment to returning value to shareholders. Comparing a company’s return on invested capital (ROIC) to the weighted average cost of capital (WACC) is another method of determining its profitability.